Showing results (301-310 of 312) with videos related to

Sort By:
Pageof 32
Blood Cancer Journal|December 14, 2020
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patientsAlissa Visram, Abdullah S Al Saleh, Harsh Parmar, et al.
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
Blood Cancer Journal|March 5, 2021
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patientsPatrick W Mellors, Surendra Dasari, Mindy C Kohlhagen, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
American Journal of Hematology|January 11, 2021
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohortMaria Eleni Drosou, Lisa E Vaughan, Eli Muchtar, et al.
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Pageof 32